Last reviewed · How we verify
CHF5259
At a glance
| Generic name | CHF5259 |
|---|---|
| Also known as | glycopyrronium bromide, GB |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Upper respiratory tract infection
- Dyspnoea
- Chronic obstructive pulmonary disease
- Nasopharyngitis
- Rhinitis
- Pyrexia
- Bronchitis
- Acute tonsillitis
- Asthma
- Cough
- Oropharyngeal pain
Key clinical trials
- A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) (PHASE1)
- Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (PHASE1, PHASE2)
- Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers (PHASE1)
- Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients (PHASE2)
- A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (PHASE2)
- Efficacy of LAMA Added to ICS in Treatment of Asthma (PHASE2)
- Triple in Asthma Dose Finding (PHASE2)
- Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF5259 CI brief — competitive landscape report
- CHF5259 updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI